echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > CTD Journal Inhaled ibuprofen salts have potential to reverse pulmonary vascular paralysis in patients with COVID-19 pneumonia

    CTD Journal Inhaled ibuprofen salts have potential to reverse pulmonary vascular paralysis in patients with COVID-19 pneumonia

    • Last Update: 2022-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recent studies have shown that an inhaled, non-hormonal anti-inflammatory drug, sodium ibuprofen (NaIHS) dissolved in hypertonic sodium salts, can relieve hypoxia symptoms in patients with moderate to severe COVID-19 pneumonia

    However, the relevant molecular mechanism is still unclear

    The authors hypothesized that the effect of NaIHS is related to indirect inhibition of high production of nitric oxide (NO) in the body

    When a patient with COVID-19 presents with symptoms of vasoplegia, we call it COVID-19 L type

    70-80% of COVID-19 patients are COVID-19 L type

    Of the 383 COVID-19 patients enrolled, 15% had been treated with mechanical ventilation

    Regardless of race, and whether it is a mechanical ventilation group or a non-mechanical ventilation group of COVID-19 patients, after correcting the respiratory rate, the patient's hypoxemia will be effectively reversed, the hospital stay will be shortened, and the mortality rate will be reduced.
    decreased, which was associated with a reduction in the half-life of gaseous NO (usually 1-5 seconds) by the treatment

    When NO harms the human body, its concentration is at the micromolar level and is concentration-dependent

    On January 23, 2022, the journal Clinical and Translational Discovery published online the latest achievement "Potential reversal of pulmonary vasoplegia by inhaled ibuprofenate in COVID-19 pneumonia" from the team of Professor Christian Carlos Zurita-Lizza in Argentina[6] ( 
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.